Vysov-M 50/1000mg (Vildagliptin/Metformin)

Brand Name: Vysov-M
Strength: 50 mg Vildagliptin / 1000 mg Metformin
Therapeutic Class: Oral Antidiabetic Agents
Dosage Form: Film-coated tablet
Prescription Status: Prescription-only medicine

Overview

Vysov-M 50/1000mg is a combination oral medicine used to regulate blood glucose levels for adults suffering from Type 2 Diabetes Mellitus (T2DM). It is composed of two active components: Vildagliptin, an inhibitor of DPP-4, and Metformin, a class of biguanide anti-diabetic drug. The two components provide additional mechanisms to help improve glycemic management more efficiently than any agent on its own.

Composition

Each Vysov-M 50/1000 mg tablet contains:

• Vildagliptin – 50 mg
• Metformin Hydrochloride (as sustained release) – 1000 mg

Indications

Vysov-M is indicated for:

• The treatment of Type 2 Diabetes Mellitus (T2DM) in adult patients:
  • In which glycemic management isn’t achieved effectively with metformin on its own.
  • In the beginning, it is a treatment option for those with hyperglycemia.
  • For triple therapy, it is recommended to combine using insulin or a sulfonylurea to treat diabetes when the dual therapy option isn’t sufficient.

Mechanism of Action

Vildagliptin (DPP-4 Inhibitor):

• Blocks the enzyme Dipeptidyl Peptidase-4 (DPP-4), which reduces the hormones incretin such as GLP-1 and GIP.
• Increases the body’s ability to regulate blood sugar through increasing:
  • Insulin production by pancreatic β-cells.
  • The suppression of the glucagon release from α-cells.
• The effects of these can be dependent on glucose and reduce the risk of developing hypoglycemia.

Metformin (Biguanide):

• Reduces hepatic glucose production (gluconeogenesis).
• Increases the sensitivity of insulin in fat and muscle tissues.
• The delay in the intestinal sugar absorption.
• It does not result in excessive weight gain and comes with an extremely low chance of developing hypoglycemia.

Together, they offer the possibility of a dual strategy–improving both the secretion of insulin as well as sensitivity to insulin, which results in better glucose control.

Benefits

• Improved Glycemic Control: It is superior to monotherapy in the reduction of HbA1c.
• Weight Neutrality: The agents do not cause weight gain.
• Low Risk of Hypoglycemia: Particularly when it is not in conjunction with the sulfonylureas.
• Convenient Dosing: Fixed-dose combination decreases the burden of pills.
• Complementary Actions: The T2DM autoimmune disorder targets multiple pathophysiological issues.

Dosage and Administration

General Dosing Guidelines:

• Dose: A tablet of Vysov M 50/1000 mg two times a day in conjunction with breakfast and dinner.
• Modify based on the patient’s treatment regimen, kidney function, and the glycemic response.
• The recommended dosage for daily use of Vildagliptin is 100 mg.
• Metformin dosage should be based on the guidelines for renal function to prevent the development of lactic acidosis.

Administration Tips:

• It is recommended to take at least one hour before meals to reduce gastrointestinal adverse effects.
• Take care not to crush or chew the tablets.
• Keep a regular check of your blood glucose levels.

Precautions and Warnings

Lactic Acidosis:

• A rare but significant risk is associated with Metformin, particularly in:
  • Renal impairment
  • Hepatic dysfunction
  • Acute illness (e.g., sepsis, dehydration)
• Symptoms: Fatigue, muscle pain, breathing difficulty, drowsiness.

Renal Function Monitoring:

• Make sure to check the eGFR at the time of initiation and every few days afterward.
• Do not start metformin if eGFR < 45 mL/min/1.73m².
• Stop the medication if the eGFR is lower than 30 mL/min/1.73m².

Hepatic Impairment:

• Do not take Vysov-M if you have liver disease due to the danger of lactic acidosis.

Cardiac Failure:

• Take care when using this method in patients suffering from heart failure.

Pancreatitis:

• A rare risk is associated with DPP-4 inhibitors, such as Vildagliptin.
• Do not stop treatment if pancreatitis is suspected.

Side Effects

Common Side Effects:

• Nausea
• Diarrhea
• Headache
• Dizziness
• Upper respiratory tract infections

Less Common/Serious Side Effects:

• Hypoglycemia (more likely when combined with sulfonylureas or insulin)
• Elevated liver enzymes
• Pancreatitis
• Lactic acidosis (rare but serious)

Be sure to report any serious or long-lasting adverse effects to your doctor.

Contraindications

• Hypersensitivity that is known to Vildagliptin, Metformin, or any other excipients.
• Moderate to extreme kidney impairment (eGFR < 45 mL/min/1.73m²).
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• Hepatic dysfunction.
• Conditions associated with hypoxia (e.g., congestive heart failure, myocardial infarction).
• Alcohol abuse.

Drug Interactions

• Alcohol: It increases the risk of contracting lactic acidosis.
• Iodinated contrast media: Stop metformin temporarily prior to taking a scan.
• Cimetidine: Could increase levels of metformin.
• Sulfonylureas/Insulin: Hypoglycemia risk when used together.

Always speak with a doctor before stopping or resuming any medication.

Use in Special Populations

Pregnancy & Lactation:

• Unrecommended due to the small amount of human-based information.
• Make use of only when clearly required and if prescribed.

Pediatric Use:

• The safety and effectiveness of this drug have not been confirmed among patients younger than 18 years old.

Elderly:

• Take care when using the product because of declining renal function due to age.

Storage Conditions

• Keep the temperature less than 30°C.
• Guard against sunlight and moisture.
• Be sure to keep away from young children.

Patient Counseling Tips

• Use the medications strictly as per the instructions.
• Keep a well-balanced eating plan as well as regular exercise.
• Always monitor the levels of blood sugar.
• Inform us of any signs related to hyperglycemia, lactic acidosis, or reactions to allergies.
• Avoid skipping doses or stopping treatment abruptly without contacting your doctor.

Clinical Evidence

The results of studies have demonstrated that Vildagliptin + Metformin combination dramatically reduces HbA1c in comparison to metformin by itself, and with the safety profile being favorable. The combination has also shown beta-cell survival as well as long-term durability of glycemic control through clinical studies.

Conclusion

Vysov-M 50/1000 mg is a potent treatment that is well-tolerated and effective to assist patients suffering from Type 2 Diabetes Mellitus attains better control of their glycemic levels. Through addressing both the issue of insulin deficiency as well as resistance to insulin the drug is an option that is effective for patients who are struggling to control their diabetes on single therapy. The dual mechanisms, the lower hypoglycemia risks, and the weight-neutrality profile make it a popular choice for those who require the long-term management of diabetes.